• About
    • Company Overview
    • Management Team
    • Board of Directors
    • Science Advisors
    • Neurology Advisors
    • Ophthalmology Advisors
    • Contacts
  • Science
    • Publications
    • Collaborators
  • Pipeline
    • Infantile Neuroaxonal Dystrophy (INAD)
    • Friedreich’s Ataxia (FA)
    • Amyotrophic Lateral Sclerosis (ALS)
    • Progressive Supranuclear Palsy (PSP)
    • Dry AMD
    • Future Targets
  • Patient Resources
    • Expanded Access Policy
    • Clinical Trials
    • Additional Resources
  • News & Events
    • Press Releases
    • News
    • Events
    • Videos
  • Careers
HomeScience AdvisorsLex Van der Ploeg, Ph.D.

Lex Van der Ploeg, Ph.D.

Dr. Van der Ploeg is an experienced biotechnology industry executive, scientist and entrepreneur with a track record of contributing both to the development of novel therapeutics, as well as successful M&A transactions.  Over the past ten years, he has been instrumental in the development of Rhythm Pharmaceuticals’ setmelanotide, Motus Therapeutics’ relamorelin (acquired by Allergan in 2016), and DeuteRx’s DRX065 (currently being developed as PXL065 following its 2018 acquisition by Poxel).  During this time, Dr. Van der Ploeg has also supported the sale of Deuteria Pharmaceuticals to Celgene.  He previously served as the senior vice president of integrative medicine and translational sciences at Abraxis Bioscience, which was acquired by Celgene in 2010.

Earlier in his career, Dr. Van der Ploeg spent more than a decade with Merck.  During his tenure, he established and grew the Merck Boston research laboratories to more than 300 scientists focused in the areas of oncology and neuroscience.  He was also responsible for the discovery of the growth-hormone secretagogue (ghrelin) receptor and contributed to the discovery of the target for ivermectin and the development of vorinostat.

In 2019, Dr. Van der Ploeg founded RIFFIT, an education technology company aimed at developing digital therapeutics to enable learning for children and adults, with diverse neurological conditions. He currently serves as the chairman and chief scientific officer for RIFFIT.  Additional current roles include senior advisor to Inkef Capital, member of the board and advisor to DeuteRx, consultant to Rhythm Pharmaceuticals, advisor to IRIS kinetics, and scientific advisor to Retrotope.  Prior to joining the industry, Dr. Van der Ploeg was a tenured faculty member at Columbia University in genetics and development working on infectious diseases.

About
Science
  • Publications
Pipeline
  • Clinical
  • Preclinical
  • Future Targets
Patient Resources
  • Expanded Access Policy
News & Events
Careers
RETROTOPE, 4300 EL CAMINO REAL, SUITE 201, LOS ALTOS, CA 94022
Copyright ©️ 2015-2021 Retrotope Inc.
You are leaving Retrotope’s website. Retrotope does not guarantee the accuracy or completeness of the information contained on any third-party sites, nor does it endorse any of the opinions or information contained on those sites. Please click CONFIRM to continue. CONFIRM